search
Back to results

Magnitude of Changes in 25 OH Vitamin D3 Levels After Vitamin D3 Supplementation

Primary Purpose

Vitamin D Deficiency

Status
Withdrawn
Phase
Phase 1
Locations
Saudi Arabia
Study Type
Interventional
Intervention
vitamin D3 1000 IU orally daily for 5 months
vitamin D3 3000 IU orally daily for 5 months
vitamin D3 5000 IU orally daily for 5 months
Placebo orally daily for 5 months
Sponsored by
King Faisal Specialist Hospital & Research Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Vitamin D Deficiency focused on measuring vitamin D3, 25 OH vitamin D3 level

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adults living in Riyadh area who consume no more than one serving of milk/day, do not take vitamin supplement, habitually have less than 10 hr of sun exposure per week, don't suffer from granulomatous conditions, liver disease, or kidney disease, and don't take anticonvulsants, barbiturates, or steroids.
  • Individuals with with total 25 OH vitamin D level exceeding 100 nmol/l will be excluded from the study. Individuals with 25 OH vitamin D levels less than 20 nmol/L will be excluded from the placebo arm.

Sites / Locations

  • King Faisal Specialist Hospital & Research Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

vitamin D3 1000 IU

Vitamin D3 3000 IU

Vitamin D3 5000 IU

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Slope of 25 OH vitamin D3 level vs vitamin D3 dose
The primary endpoint is the slope of the dose (vitamin D3)- response (25 OH vitamin D3 level) curve for each cohort. The slope of the placebo group will be used to determine changes in 25 OH vitamin D3 levels that are not related to study intervention. The slope will be determined over 5 months.

Secondary Outcome Measures

slope of vitamin D3 level vs vitamin D3 dose
slope of vitamin D3 level vs vitamin D3 dose over 5 months
incidence of hypercalcemia
incidence of hypercalcemia over 8 months
incidence of hypercalciuria
incidence of hypercalciuria over 8 months
slope of decline of 25 OH vitamin D3 level vs time
slope of decline of 25 OH vitamin D3 level vs time over 3 months

Full Information

First Posted
July 25, 2010
Last Updated
March 6, 2018
Sponsor
King Faisal Specialist Hospital & Research Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01170507
Brief Title
Magnitude of Changes in 25 OH Vitamin D3 Levels After Vitamin D3 Supplementation
Official Title
Magnitude of Changes in 25 OH Vitamin D3 Levels After Vitamin D3 Supplementation: A Randomized Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Withdrawn
Why Stopped
No funding
Study Start Date
December 2011 (undefined)
Primary Completion Date
August 2016 (Actual)
Study Completion Date
August 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
King Faisal Specialist Hospital & Research Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Vitamin D deficiency is common world wide. 25 OH vitamin D level is the best indicator of vitamin D status. The determination of the appropriate dose of vitamin D supplement is essential for management of vitamin D deficiency as well as for designing vitamin D fortification programs. The increments in 25 OH vitamin D levels following various doses of vitamin D supplement for different genders, body weights, and starting 25 OH vitamin D level have not been well defined. The time course of depletion of repleted vitamin D stores is also not known. The investigators plan to conduct a double blind randomized study on 9 cohorts to determine levels of 25 OH vitamin D following supplementation with different doses of vitamin D3 for 5 months and their withdrawal for 3 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency
Keywords
vitamin D3, 25 OH vitamin D3 level

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
vitamin D3 1000 IU
Arm Type
Active Comparator
Arm Title
Vitamin D3 3000 IU
Arm Type
Active Comparator
Arm Title
Vitamin D3 5000 IU
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
vitamin D3 1000 IU orally daily for 5 months
Intervention Type
Drug
Intervention Name(s)
vitamin D3 3000 IU orally daily for 5 months
Intervention Type
Drug
Intervention Name(s)
vitamin D3 5000 IU orally daily for 5 months
Intervention Type
Drug
Intervention Name(s)
Placebo orally daily for 5 months
Primary Outcome Measure Information:
Title
Slope of 25 OH vitamin D3 level vs vitamin D3 dose
Description
The primary endpoint is the slope of the dose (vitamin D3)- response (25 OH vitamin D3 level) curve for each cohort. The slope of the placebo group will be used to determine changes in 25 OH vitamin D3 levels that are not related to study intervention. The slope will be determined over 5 months.
Time Frame
5 months
Secondary Outcome Measure Information:
Title
slope of vitamin D3 level vs vitamin D3 dose
Description
slope of vitamin D3 level vs vitamin D3 dose over 5 months
Time Frame
5 months
Title
incidence of hypercalcemia
Description
incidence of hypercalcemia over 8 months
Time Frame
8 months
Title
incidence of hypercalciuria
Description
incidence of hypercalciuria over 8 months
Time Frame
8 months
Title
slope of decline of 25 OH vitamin D3 level vs time
Description
slope of decline of 25 OH vitamin D3 level vs time over 3 months
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adults living in Riyadh area who consume no more than one serving of milk/day, do not take vitamin supplement, habitually have less than 10 hr of sun exposure per week, don't suffer from granulomatous conditions, liver disease, or kidney disease, and don't take anticonvulsants, barbiturates, or steroids. Individuals with with total 25 OH vitamin D level exceeding 100 nmol/l will be excluded from the study. Individuals with 25 OH vitamin D levels less than 20 nmol/L will be excluded from the placebo arm.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Muhammad M Hammami, MD, PhD
Organizational Affiliation
King Faisal Specialist Hospital & Research Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
King Faisal Specialist Hospital & Research Center
City
Riyadh
ZIP/Postal Code
11211
Country
Saudi Arabia

12. IPD Sharing Statement

Learn more about this trial

Magnitude of Changes in 25 OH Vitamin D3 Levels After Vitamin D3 Supplementation

We'll reach out to this number within 24 hrs